Symptomatic Infantile Spasms After First-Line Therapy Fails to Achieve Complete Spasm Cessation
This protocol addresses infants with symptomatic infantile spasms—characterised by abnormal neurodevelopment and/or a clear underlying etiology, excluding tuberous sclerosis—in whom an initial treatment switch did not achieve the required response.
Clinical scenario
Symptomatic infantile spasms in the context of abnormal development and/or an identifiable etiology (tuberous sclerosis excluded). The patient has already received an alternative first-line agent without achieving adequate spasm control.
Prior therapy — target not reached
A switch to an alternative first-line agent (ACTH, prednisolone, or vigabatrin) was trialled with the goal of complete cessation of spasms and resolution of hypsarrhythmia on video EEG, typically assessed at 14 days. That target was not reached, indicating that a further therapeutic step is required.
Next-step approach (partial summary)
When established first-line options have not achieved spasm freedom, a range of alternative approaches—including specialised dietary therapy and select antiepileptic agents—may be considered. The full structured regimen details all options and their specific monitoring requirements.
Treatment goal
Complete cessation of spasms. Spasm freedom with certain approaches has been reported within 1–3 months.
References
DOI: 10.3978/j.issn.2224-4336.2015.09.01
- Defines symptomatic infantile spasms as those patients with either abnormal development and/or a clear etiology for the infantile spasms and cryptogenic spasms as those occurring in the context of normal development without a clear etiology.
- Many other treatment options continue to be explored, including the ketogenic diet, traditional anti-epileptic medications, and resective surgery in select cases.
- The goal of treatment of infantile spasms remains complete cessation of spasms.
- Spasm freedom has been reported in 14–65% of patients within 1–3 months.
View source ↗